Skyline Therapeutics Receives the US FDA’s IND Clearance of SKG0106 for Neovascular Age-related Macular Degeneration
Shots:
- The US FDA has cleared an IND application to initiate the P-I/IIa trial evaluating SKG0106, a novel intravitreally delivered AAV gene therapy for nAMD. The trial is expected to be initiated shortly
- SKG0106 showed a potent efficacy of inhibition of intraocular neovascularization in comprehensive preclinical studies with a favorable safety profile, and long-lasting durability, following a single IVT administration
- SKG0106 was a safe and effective anti-angiogenic therapy in preclinical proof-of-concept tests, with durable suppression of neovascular lesions with a low-dose single IVT injection. This prevented choroidal or retinal neovascularization and relieved retinal edoema and vascular leakage
Ref: Skyline | Image: Skyline
Related News:- BioMarin Collaborates with Skyline to Develop and Commercialize AAV Gene Therapies for Genetic Cardiovascular Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
